Aquivia Health Review
Best for: Self-pay patients who want a clinician-reviewed (not algorithmic) compounded-GLP-1 pathway at the low end of the WLR compounded cluster ($149/mo semaglutide, $179/mo tirzepatide) AND want the option to upgrade to branded Ozempic/Zepbound at the same operator. Buyers who value a named clinical MSO partner (Open Loop Healthcare Partners, PC) and a co-founder team that publicly discloses credentials (MD + PharmD + operations executive). NOT ideal for buyers who require an upfront state-availability disclosure (Aquivia does not publish a state allowlist), buyers who require LegitScript/PCAB/BBB badges in the footer as a precondition (none visible in this verification pass), or buyers in coming-soon program categories (Performance Longevity, Dysautonomia/POTS are waitlist-only).
Aquivia Health is a clinician-led DTC telehealth platform (operating under the CatalystMD parent brand per the homepage Schema.org Organization markup) offering compounded GLP-1 weight loss therapy and branded Ozempic/Zepbound through a self-pay model. Clinical care is delivered by partner clinicians at Open Loop Healthcare Partners, PC (openloophealth.com) — the same MSO network used by several other DTC GLP-1 brands. Compounded medication is sourced from licensed 503A compounding pharmacies (network, no single pharmacy partner named publicly). Pricing: Compounded Semaglutide $149/mo and Compounded Tirzepatide $179/mo on 4-week cadence (same price for all doses), branded Ozempic $1,299/shipment and branded Zepbound $1,399/shipment per 4-week fill. Multi-month bundles (12/24/52 weeks) discounted (e.g., 52-week semaglutide one-time payment $2,327 / 13 shipments = ~$179/shipment; 52-week tirzepatide $3,497 = ~$269/shipment, both 'save $910 vs billed every 4 weeks'). Three co-founders disclosed: Steven Bishop, MD (Internal Medicine, Chief Medical Officer), Phillip Gray, PharmD (Chief Pharmacist, 503A/USP background), and Tom Foster (President). Marketed as 'Nationwide distribution *where allowed by state law' — no public state allowlist disclosed; eligibility varies by state per FAQ. Coming-soon Performance Longevity and Dysautonomia/POTS programs are waitlist-only. Listed contact phone 804-963-8235, clinical support support@aquiviahealth.com.
Low confidence · Last verified 2026-05-29 · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Aquivia Health is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Aquivia Health prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded semaglutide, 4-week supply (same price all doses) | subcutaneous injection | $149 |
| Compounded tirzepatide, 4-week supply (same price all doses) | subcutaneous injection | $179 |
| Compounded semaglutide, 52-week prepay (13 shipments, $2,327 one-time) | subcutaneous injection | $179 |
| Compounded tirzepatide, 52-week prepay (13 shipments, $3,497 one-time) | subcutaneous injection | $269 |
| Branded Ozempic, 4-week supply (semaglutide, all doses) | prefilled injection pen | $1299 |
| Branded Zepbound, 4-week supply (tirzepatide, all doses) | prefilled injection pen / vial | $1399 |
✓ Pros
- •Named clinical partner disclosed verbatim in site footer: 'Clinical care services provided by our partner clinicians at Open Loop Healthcare Partners, PC: openloophealth.com' — same MSO network used by several other DTC GLP-1 brands, which is a reused-and-verified trust signal
- •Named leadership team with credentials disclosed: Steven Bishop MD (CMO, Internal Medicine), Phillip Gray PharmD (Chief Pharmacist, 503A/USP background), Tom Foster (President)
- •Itemized pricing displayed publicly on /pricing and /programs/glp-1-weight-loss — Compounded Semaglutide $149/mo, Compounded Tirzepatide $179/mo, Ozempic $1,299/shipment, Zepbound $1,399/shipment
- •Both compounded AND branded GLP-1 options offered side-by-side, which is unusual — most DTC compounded providers do not also carry branded Ozempic/Zepbound
- •Self-pay model with no insurance required and no separate consultation fee (consult bundled into the monthly product price)
- •Multi-month prepay discounts disclosed publicly ('save $910 vs billed every 4 weeks' on 52-week semaglutide and tirzepatide tiers)
- •Explicit no-guarantee disclaimer ('Completing the check does not guarantee a prescription') is a positive clinical-safety signal vs platforms that imply guaranteed prescriptions
- •Multi-program platform with metabolic, longevity, and dysautonomia pathways (latter two waitlist-only) suggests a broader clinical scope than single-vertical compounded shops
✗ Cons
- •No public state-availability allowlist — marketing copy says 'Nationwide distribution *where allowed by state law' but the FAQ acknowledges 'Not all therapies are available in every state' without disclosing which states are excluded; buyer must complete the eligibility intake to learn whether their state qualifies
- •No named 503A compounding pharmacy partner disclosed publicly — the homepage and pricing page reference '503A Pharmacy Standard' and 'licensed 503A compounding pharmacies' but do not name a specific pharmacy operator, limiting independent licensure verification
- •No LegitScript, PCAB, or BBB trust-signal badges visible on the homepage footer in this verification pass — a meaningful omission for a DTC compounded-GLP-1 platform launched 2026-Q1 (site Schema.org datePublished 2026-04-21)
- •Brand confusion risk: schema.org Organization name on the homepage is 'CatalystMD' (with a CatalystMD logo file referenced) while the customer-facing brand is 'Aquivia Health' — the parent/operating-entity relationship is not disclosed in the public footer or About page in this verification pass
- •Compounded semaglutide and tirzepatide are not FDA-approved and have not undergone FDA premarket review for safety, efficacy, or manufacturing quality
- •Site is recently launched (Schema.org datePublished 2026-04-21, dateModified 2026-05-24) with no Trustpilot, BBB, or third-party-reviews profile yet that could be independently verified
- •Two of the three advertised programs (Performance Longevity, Dysautonomia/POTS) are waitlist-only — only the GLP-1 Weight Loss / Metabolic Health pathway is currently 'Available Now'
Sources & methodology
Our Aquivia Health review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
Alternatives to Aquivia Health
Belle Health
Best for: Cost-sensitive patients comfortable with the Feb-2026 FDA warning, wanting flat-rate pricing and dietitian-included support
Editorial score · methodology
Bodybuilding Health+
Best for: fitness-oriented patients who want compounded GLP-1 alongside hormone and performance programs from a 25-year-old established brand
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory